skip to main content

Lung Cancer

Coping with COVID and then cancer

Andrew Ackerman was the first COVID-19 patient to be treated with an experimental filter that reduced his inflammation, helping to save his life. Later, during his COVID recovery, doctors learned Ackerman had a lung tumor.

The importance of reducing heart exposure during radiation treatment

A team at the University of Michigan Health Rogel Cancer Center, in partnership with the statewide Michigan Radiation Oncology Quality Consortium, or MROQC, lung cancer collaborative, co-led by Shruti Jolly, M.D., and Peter Paximadis, M.D., of Spectrum Health Lakeland in St. Joseph, Michigan, found that raising awareness about the risk of radiation exposure to the heart and standardizing cardiac exposure limits reduced the average dose to the heart by 15% and reduced the number of patients receiving the highest heart doses by half without minimizing tumor treatment or increasing dosage to other at-risk organs in the chest.

$7.6 million gift launches new lung cancer research initiative at U-M

A $7.6 million gift from Judith L. Tam and the Richard Tam Foundation has launched an accelerated research initiative here at the Rogel Cancer Center to understand why alterations in the ALK gene causes lung cancer to become resistant to standard therapy over time.

The protein AGO2 may be the key to blocking the KRAS gene and slowing lung cancer growth

Research suggests stopping the interaction between KRAS and the protein AGO2 slowed tumor growth in mouse models and lead to better treatment for non-small cell lung cancer.

Rogel Cancer Center names clinical research young investigators

The awards recognize faculty members’ outstanding clinical research and promising future in oncology.

Expanded lung cancer screening eligibility would save lives

The modeling study looks at the benefits and harms associated with various low-dose computed tomography screening strategies—identifying those that result in the most benefits for a given level of screening.

New inhibitor shows promise against challenging lung, colon cancers

A new inhibitor designed to target what’s been called an “undruggable” genetic mutation showed promising activity against advanced cancers with this mutation.

Pages